Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data-Reference-Cited by-同舟云学术

Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data

Published:2018-09-11 Issue:10 Volume:35 Page:1612-1625
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Yan Tingjian,Greene Mallik,Chang Eunice,Hartry Ann,Touya Maëlys,Broder Michael S.

Funder

Otsuka Pharmaceutical Development and Commercialization, Inc. and Lundbeck

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-018-0785-y.pdf

Reference51 articles.

1. The National Institute of Mental Health. Schizophrenia [Internet]. health & education—statistics. 2018. https://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtml . Accessed 30 Nov 2017.

2. The National Institute of Mental Health. Bipolar disorder [Internet]. Health & education—statistics. 2017. https://www.nimh.nih.gov/health/statistics/prevalence/bipolar-disorder-among-adults.shtml . Accessed 30 Nov 2017.

3. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381:1672–82.

4. Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ. 2012;345:e8508.

5. Zullig LL, Peterson ED, Bosworth HB. Ingredients of successful interventions to improve medication adherence. JAMA. 2013;310:2611.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medication burden reduction and early clinical benefit through aripiprazole once monthly in schizophrenia patients with polypharmacy;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-12

2. The new long-acting injectable for maintenance treatment of schizophrenia: What is the clinical value of aripiprazole 2-month ready-to-use 960 mg?;The European Journal of Psychiatry;2024-07

3. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder;Clinical Pharmacology in Drug Development;2024-04-11

4. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study;Frontiers in Psychiatry;2023-08-04

5. Association of Attenuated Niacin Response With Inflammatory Imbalance and Prediction of Conversion to Psychosis From Clinical High-risk Stage;The Journal of Clinical Psychiatry;2023-07-17